Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | BTK | Q06187 | 3/20 | 0.40 |
| ▸ | LPL | P06858 | 7/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
| ▸ | KRAS | P01116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30796761 | 0.83 | JAK2 (0.37) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL30677130 | 0.83 | JAK2 (0.38) | JAK2BTKLPLLIPG | |
| SCHEMBL31651877 | 0.83 | JAK2 (0.38) | JAK2BTKLPLLIPGUCHL1 | |
| SCHEMBL23053994 | 0.83 | JAK2 (0.38) | JAK2BTKLPLLIPGLIPE | |
| SCHEMBL29878903 | 0.83 | JAK2 (0.38) | JAK2BTKLPLLIPGLIPE | |
| SCHEMBL15698566 | 0.81 | LPL (0.36) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL14709323 | 0.80 | LPL (0.35) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL23462245 | 0.80 | LPL (0.38) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL1722908 | 0.80 | CA1 (0.41) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL31098369 | 0.80 | LPL (0.35) | JAK2BTKLPLLIPGEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296938-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2025-09-25 | — | — | US | disclosed |
| US-12391705-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY THERAPEUTICS, LLC (US) | 2025-08-19 | — | — | US | disclosed |
| US-20230078755-A1 | Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY THERAPEUTICS, LLC | 2023-03-16 | — | — | US | disclosed |
| EP-3898609-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | Shy Therapeutics LLC (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113292502-A | Novel 4-aminopyridine and 6-aminopyrimidine carboxylates as herbicides | 美国陶氏益农公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2020132071-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND F1BROTIC DISEASE | SHY THERAPEUTICS. LLC (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-2967057-B1 | NOVEL 4-AMINOPYRIDINE AND 6-AMINOPYRIMIDINE CARBOXYLATES AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2967057-A1 | NOVEL 4-AMINOPYRIDINE AND 6-AMINOPYRIMIDINE CARBOXYLATES AS HERBICIDES | Dow AgroSciences LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| WO-2014150809-A1 | NOVEL 4-AMINOPYRIDINE AND 6-AMINOPYRIMIDINE CARBOXYLATES AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014150809-A1 | NOVEL 4-AMINOPYRIDINE AND 6-AMINOPYRIMIDINE CARBOXYLATES AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078755-A1 | Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | JAK2 2324/4885BTK 2377/4885LPL 3448/4885 |
| US-12391705-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | JAK2 2324/4885BTK 2377/4885LPL 3448/4885 |
| US-20250296938-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | JAK2 2324/4885BTK 2377/4885LPL 3448/4885 |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | JAK2 1714/4885BTK 311/4885LPL 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.